|
| |
Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success
|
Published: Jan 2012 | Pages: 152 | Pub ID: MM1326971635 |
|
|
|
 |
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Endpoints - Clinical Trials In Cardiovascular Disorders - Overview
2.1 Introduction
2.2 Types of Endpoints
2.2.1 Primary Endpoints
2.2.2 Secondary Endpoints
2.3 GBI Research Report Guidance
3 Endpoints - Clinical Trials In Cardiovascular Disorders - Major Endpoints of Top Five Cardiovascular Disorders
3.1 Endpoints - Major Marketed Drugs of Top Five Cardiovascular Disorders and their Regulatory Approval
3.1.1 Atherosclerosis
3.1.2 Atrial Fibrillation
3.1.3 Dyslipidemia
3.1.4 Hypertension
3.1.5 Venous Thromboembolism
4 Endpoints - Clinical Trials In Cardiovascular Disorders - Marketed and Pipeline Product Assessment
4.1 Atherosclerosis
4.1.1 Primary Endpoints Used in Atherosclerosis Clinical Trials
4.1.2 Secondary Endpoints Used in Atherosclerosis Clinical Trials
4.1.3 Major Marketed Drugs - Safety and Efficacy Analysis
4.1.4 Phase III Clinical Trial Analysis
4.1.5 Most Promising Drug’s Profile
4.1.6 Phase II Clinical Trial Analysis
4.1.7 Terminated Trials Analysis
4.2 Atrial Fibrillation
4.2.1 Primary Endpoints Used in Atrial Fibrillation
4.2.2 Secondary Endpoints Used in Atrial Fibrillation
4.2.3 Major Marketed Drugs - Safety and Efficacy Analysis
4.2.4 Phase III Clinical Trial Analysis
4.2.5 Most Promising Drug’s Profile
4.2.6 Phase II Clinical Trial Analysis
4.2.7 Terminated Trials Analysis
4.3 Dyslipidemia
4.3.1 Primary Endpoints Used in Dyslipidemia
4.3.2 Secondary Endpoints Used in Dyslipidemia
4.3.3 Major Marketed Drugs - Safety and Efficacy Analysis
4.3.4 Phase III Clinical Trial Analysis
4.3.5 Most Promising Drug’s Profile
4.3.6 Phase II Clinical Trial Analysis
4.3.7 Terminated Trials Analysis
4.4 Hypertension
4.4.1 Primary Endpoints Used in Hypertension
4.4.2 Secondary Endpoints Used in Hypertension
4.4.3 Major Marketed Drugs - Safety and Efficacy Analysis
4.4.4 Phase III Clinical Trial Analysis
4.4.5 Most Promising Drug’s Profile
4.4.6 Phase II Clinical Trial Analysis
4.4.7 Terminated Trials Analysis
4.5 Venous Thromboembolism
4.5.1 Primary Endpoints Used in Venous Thromboembolism
4.5.2 Secondary Endpoints Used in Venous Thromboembolism
4.5.3 Major Marketed Drugs - Safety and Efficacy Analysis
4.5.4 Phase III Clinical Trial Analysis
4.5.5 Most Promising Drug’s Profile
4.5.6 Phase II Clinical Trial Analysis
4.5.7 Terminated Trials Analysis
5 Endpoints - Clinical Trials In Cardiovascular Disorders - Competitive Landscape
5.1 Pfizer Inc.
5.1.1 Company Overview
5.1.2 Major Cardiovascular Drugs Marketed by Pfizer
5.2 Sanofi S.A.
5.2.1 Company Overview
5.2.2 Major Cardiovascular Drugs Marketed by Sanofi S.A.
5.3 Novartis AG
5.3.1 Company Overview
5.3.2 Major Cardiovascular Drugs Marketed by Novartis AG
5.4 AstraZeneca PLC
5.4.1 Company Overview
5.4.2 Major Cardiovascular Drugs Marketed by AstraZeneca PLC
5.5 Boehringer Ingelheim GmbH
5.5.1 Company Overview
5.5.2 Major Cardiovascular Drugs Marketed by Boehringer Ingelheim GmbH
5.6 Actelion Ltd.
5.6.1 Company Overview
5.6.2 Major Cardiovascular Drugs Marketed by Actelion Ltd.
5.7 Daiichi Sankyo Company Ltd.
5.7.1 Company Overview
5.7.2 Major Cardiovascular Drugs Marketed by Daiichi Sankyo Company Ltd.
5.8 Abbott Laboratories
5.8.1 Company Overview
5.8.2 Major Cardiovascular Drugs Marketed by Abbott Laboratories
5.9 Bayer AG
5.9.1 Company Overview
5.9.2 Major Cardiovascular Drugs Marketed by Bayer AG
5.10 GlaxoSmithKline PLC
5.10.1 Company Overview
5.10.2 Major Cardiovascular Drugs Marketed by GlaxoSmithKline PLC
6 Endpoints - Clinical Trials In Cardiovascular Disorders - Appendix
6.1 Market Definitions
6.2 Abbreviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Primary Research
6.3.4 Section Methodology
6.3.5 Expert Panel Validation
6.4 Contact Us
6.5 Disclaimer
6.6 Sources |
|
| By: GBI Research |
|
|
| |
|
|
|
US Office
India Office